Celecoxib and LLW-3-6 Reduce Survival of Human Glioma Cells Independently and Synergistically with Sulfasalazine

Article Figures & Data

Download figure
Open in new tab
Download powerpoint
Figure 1.
Calculated size and lipophilicity of celecoxib and LLW-3-6. The values were obtained using ChemBio Office (PerkinElmer, Inc., Waltham, MA, USA). The size is calculated as the molar refractivity. The lipophilicity was calculated as the octanol/water partition coefficient (logP). The size- to-lipophilicity ratios for the molecules are similar, to that of LLW-3-6 being more favorable than that of celecoxib.
Download figure
Open in new tab
Download powerpoint
Figure 2.
Effects of single-dose treatment with either celecoxib (CBX; A) or LLW-3-6 (LLW; B) and combination treatment with celecoxib/sulfasalazine (CBX-SAS) or LLW-3-6/sulfasalazine (LLW-SAS) on glioma cell survival at 24 and 48 h. A non-lethal dose of sulfasalazine (50 μM) was used with different concentrations of celecoxib and LLW-3-6 for the co-treatments. Effects were measured following 24- and 48-h incubation periods using a modified MTT assay.
Download figure
Open in new tab
Download powerpoint
Figure 3.
Effects on glioma cells of treatment with celecoxib (CBX; A-C) and LLW-3-6 (LLW; D-F) in combination with sulfasalazine for a 48-h incubation period. The combination effects were evaluated based on values generated in the CompuSyn software; combination index (CI; A and D), the normalized isobologram (B and E), and the dose reduction index (DRI; C and F). Both CI and logDRI are plotted against the effect level (Fa).